We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals
XFOR

93 hedge funds and large institutions have $23.6M invested in X4 Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

552% more call options, than puts

Call options by funds: $202K | Put options by funds: $31K

50% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 10

27% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 22

4% more funds holding

Funds holding: 89 → 93 (+4)

0.06% less ownership

Funds ownership: 1.95% → 1.89% (-0.06%)

68% less capital invested

Capital invested by funds: $73.2M → $23.6M (-$49.7M)

Holders
93
Holders Change
+4
Holders Change %
+4.49%
% of All Funds
1.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
28
Reduced
22
Closed
10
Calls
$202K
Puts
$31K
Net Calls
+$171K
Net Calls Change
-$245K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$1.89M
2
KCM
Kingdon Capital Management
New York
+$947K
3
PFCS
Pale Fire Capital SE
Czech Republic
+$291K
4
BlackRock
BlackRock
New York
+$170K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$56.2K

Top Sellers

Rank Fund Capital Flow
1
Axa
Axa
France
-$1.09M
2
GCP
GSA Capital Partners
United Kingdom
-$934K
3
SSA
Schonfeld Strategic Advisors
New York
-$485K
4
UOC
UBS O'Connor
Illinois
-$465K
5
Group One Trading
Group One Trading
Illinois
-$287K
Name Holding Trade Value Shares
Change 		Change in
Stake
Pathstone Holdings
76
Pathstone Holdings
New Jersey
$2.99K – – –
California State Teachers Retirement System (CalSTRS)
77
California State Teachers Retirement System (CalSTRS)
California
$2.88K – – –
ACM
78
Allred Capital Management
Texas
$2.73K +$5.3K +385 New
HSA
79
HBK Sorce Advisory
Pennsylvania
$2.63K +$303 +22 +6%
X
80
Xponance
Pennsylvania
$2.61K +$124 +9 +3%
AIP
81
Ameritas Investment Partners
Nebraska
$2.4K – – –
1IA
82
1620 Investment Advisors
Massachusetts
$2.36K – – –
LCM
83
Lazari Capital Management
California
$2.36K – – –
BTI
84
Blue Trust Inc
Georgia
$2.01K – – –
Carson Wealth (CWM LLC)
85
Carson Wealth (CWM LLC)
Nebraska
$2K +$3.32K +241 +344%
SS
86
SBI Securities
Japan
$1.52K +$2.44K +177 +478%
AB
87
Amalgamated Bank
New York
$1K – – –
Jones Financial Companies
88
Jones Financial Companies
Missouri
$286 +$523 +38 New
RP
89
Raelipskie Partnership
Ontario, Canada
$236 – – –
NA
90
NewEdge Advisors
Louisiana
$236 +$455 +33 New
HWM
91
HighMark Wealth Management
Minnesota
$43 – – –
SCM
92
Sterling Capital Management
North Carolina
$41 – – –
EWA
93
EverSource Wealth Advisors
Alabama
$7 – – –
FFA
94
Frazier Financial Advisors
Ohio
$3 – – –
GCP
95
GSA Capital Partners
United Kingdom
– -$934K -42,455 Closed
Jane Street
96
Jane Street
New York
– -$268K -19,449 Closed
DMKJ
97
David M. Knott Jr
– -$113K -5,136 Closed
Vontobel Holding
98
Vontobel Holding
Switzerland
– -$55K -2,500 Closed
AWS
99
Atria Wealth Solutions
New York
– -$44K -2,000 Closed
Wolverine Trading
100
Wolverine Trading
Illinois
– -$32.1K -1,322 Closed
1 2 3
4
5

XFOR Hedge Fund Activity: Q1 2025 in Review

93 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2025, worth a combined $23.6M — down 68% from $73.2M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new XFOR positions and 10 closed out — a net gain of 5 holders — while 28 added to existing stakes and 22 trimmed.

The largest buyer was UBS Group, adding an estimated $1.89M. The largest seller was Axa, cutting an estimated $1.09M.

  • 93 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2025, up from 89 in Q4 2024.
  • Funds reported $23.6M of X4 Pharmaceuticals stock for Q1 2025, down 68% quarter-over-quarter.
  • 15 funds opened new X4 Pharmaceuticals positions in Q1 2025 and 10 closed out, a net change of +5 holders.
  • The largest X4 Pharmaceuticals buyer in Q1 2025 was UBS Group, an estimated $1.89M added.
  • The largest X4 Pharmaceuticals seller in Q1 2025 was Axa, an estimated $1.09M sold.

Based on aggregated 13F filings for Q1 2025.